Literature DB >> 17721087

Endogenous K-ras signaling in erythroid differentiation.

Jing Zhang1, Harvey F Lodish.   

Abstract

K-ras is one of the most frequently mutated genes in virtually all types of human cancers. Using mouse fetal liver erythroid progenitors as a model system, we studied the role of endogenous K-ras signaling in erythroid differentiation. When oncogenic K-ras is expressed from its endogenous promoter, it hyperactivates cytokine-dependent signaling pathways and results in a partial block in erythroid differentiation. In erythroid progenitors deficient in K-ras, cytokine-dependent Akt activation is greatly reduced, leading to delays in erythroid differentiation. Thus, both loss- and gain-of-Kras functions affect erythroid differentiation through modulation of cytokine signaling. These results support the notion that in human cancer patients oncogenic Ras signaling might be controlled by antagonizing essential cytokines.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17721087     DOI: 10.4161/cc.6.16.4577

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  16 in total

Review 1.  From stem cell to red cell: regulation of erythropoiesis at multiple levels by multiple proteins, RNAs, and chromatin modifications.

Authors:  Shilpa M Hattangadi; Piu Wong; Lingbo Zhang; Johan Flygare; Harvey F Lodish
Journal:  Blood       Date:  2011-10-12       Impact factor: 22.113

2.  Critical function for the Ras-GTPase activating protein RASA3 in vertebrate erythropoiesis and megakaryopoiesis.

Authors:  Lionel Blanc; Steven L Ciciotte; Babette Gwynn; Gordon J Hildick-Smith; Eric L Pierce; Kathleen A Soltis; Jeffrey D Cooney; Barry H Paw; Luanne L Peters
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-06       Impact factor: 11.205

3.  Theoretical and experimental analysis links isoform-specific ERK signalling to cell fate decisions.

Authors:  Marcel Schilling; Thomas Maiwald; Stefan Hengl; Dominic Winter; Clemens Kreutz; Walter Kolch; Wolf D Lehmann; Jens Timmer; Ursula Klingmüller
Journal:  Mol Syst Biol       Date:  2009-12-22       Impact factor: 11.429

4.  Defective erythroid differentiation in miR-451 mutant mice mediated by 14-3-3zeta.

Authors:  David M Patrick; Cheng C Zhang; Ye Tao; Huiyu Yao; Xiaoxia Qi; Robert J Schwartz; Lily Jun-Shen Huang; Eric N Olson
Journal:  Genes Dev       Date:  2010-08-01       Impact factor: 11.361

Review 5.  Role of Ras/Raf/MEK/ERK signaling in physiological hematopoiesis and leukemia development.

Authors:  Eva Chung; Motonari Kondo
Journal:  Immunol Res       Date:  2011-04       Impact factor: 2.829

Review 6.  Dysregulated myelopoiesis and hematopoietic function following acute physiologic insult.

Authors:  Tyler J Loftus; Alicia M Mohr; Lyle L Moldawer
Journal:  Curr Opin Hematol       Date:  2018-01       Impact factor: 3.284

7.  Oncogenic NRAS hyper-activates multiple pathways in human cord blood stem/progenitor cells and promotes myelomonocytic proliferation in vivo.

Authors:  Tongjie Wang; Chen Li; Chengxiang Xia; Yong Dong; Dan Yang; Yang Geng; Jizhen Cai; Jing Zhang; Xiangzhong Zhang; Jinyong Wang
Journal:  Am J Transl Res       Date:  2015-10-15       Impact factor: 4.060

Review 8.  Nonredundant functions for Ras GTPase-activating proteins in tissue homeostasis.

Authors:  Philip D King; Beth A Lubeck; Philip E Lapinski
Journal:  Sci Signal       Date:  2013-02-26       Impact factor: 8.192

9.  Kras is Required for Adult Hematopoiesis.

Authors:  Alisa Damnernsawad; Guangyao Kong; Zhi Wen; Yangang Liu; Adhithi Rajagopalan; Xiaona You; Jinyong Wang; Yun Zhou; Erik A Ranheim; Hongbo R Luo; Qiang Chang; Jing Zhang
Journal:  Stem Cells       Date:  2016-03-28       Impact factor: 6.277

10.  SH2B3 (LNK) mutations from myeloproliferative neoplasms patients have mild loss of function against wild type JAK2 and JAK2 V617F.

Authors:  Maya Koren-Michowitz; Sigal Gery; Takayuki Tabayashi; Dechen Lin; Rocio Alvarez; Arnon Nagler; H Phillip Koeffler
Journal:  Br J Haematol       Date:  2013-04-17       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.